PC
GPCR icon

Pier Capital’s Structure Therapeutics GPCR Stock Holding History

Pier Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,551
Closed -$2.29M – 138
2026
Q1 		$2.29M Sell
47,551
-1,206
-2% -$82.5K 0.38% 93
2025
Q4 		$3.39M Sell
48,757
-148,752
-75% -$6.07M 0.54% 89
2025
Q3 		$5.53M Sell
197,509
-969
-0.5% -$19.3K 0.86% 58
2025
Q2 		$4.12M Sell
198,478
-14,042
-7% -$309K 0.63% 76
2025
Q1 		$3.68M Buy
212,520
+79,916
+60% +$1.96M 0.62% 79
2024
Q4 		$3.6M Sell
132,604
-1,687
-1% -$59.9K 0.51% 83
2024
Q3 		$5.89M Buy
134,291
+33,087
+33% +$1.28M 0.83% 66
2024
Q2 		$3.97M Buy
101,204
+3,647
+4% +$150K 0.59% 85
2024
Q1 		$4.18M Buy
97,557
+61,904
+174% +$2.61M 0.58% 82
2023
Q4 		$1.45M Buy
+35,653
New +$2.04M 0.21% 94

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pier Capital's GPCR Position: Q2 2026 in Review

Pier Capital sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 47,551 shares — an estimated $2.29M sold.

Pier Capital first reported a position in GPCR in Q4 2023 and held it in 10 quarters. The position peaked at $5.89M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Pier Capital reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pier Capital sold 47,551 Structure Therapeutics shares in Q2 2026, an estimated $2.29M.
  • Pier Capital first reported a position in Structure Therapeutics in Q4 2023 and held it in 10 quarters.
  • Pier Capital's Structure Therapeutics position peaked at $5.89M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.